Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ACIP Support Of FDA-Approved Prevnar 13 Creates Prospect For Larger Market

Executive Summary

In a long-awaited move, the FDA approved on Feb. 23 Pfizer's Prevnar 13 vaccine for pneumococcal disease in children 5 years of age and younger, a crucial step in the drug maker's ability to build out the vaccine franchise that was central to its acquisition last year of Wyeth

You may also be interested in...

13 Going On 50: Pfizer Seeks Adult Indication For Prevnar

Advisory committee might closely scrutinize the requested indication for the 13-valent pneumococcal conjugate vaccine for adults age 50 and up; it is now indicated for children under six years old.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts